

Advancing the Pipeline on Key Programs

Estimated timelines		2017	2018	2019	2020
WH	ESMYA <i>Uterine fibroids</i>		FDA meeting		
CNS	Ubrogepant <i>Acute migraine</i>	Ph. III recruitment complete	✓ Ph. III topline results		Launch
	Atogepant <i>Prophylaxis migraine</i>		✓ Ph. IIb topline results	Ph. III initiation	
	Cariprazine <i>Bipolar Depression</i>	Positive Ph. III topline	✓ Positive 3 rd Ph. III topline	Launch	
	Rapastinel <i>Depression</i>	Ph. III on track		Ph. III topline results	Maintenance topline results
EYE	Abicipar <i>AMD/DME</i>		✓ Ph. III topline results (AMD)	Maple study results(AMD) Ph. III initiation (DME)	Launch (AMD)
	Brimonidine DDS <i>Geographic Atrophy</i>		✓ Ph. 2b topline results	Ph. III initiation	
	Bimatoprost SR <i>Glaucoma</i>		✓ 1 st Ph. III topline results	2 nd Ph. III topline results	Launch
	Pilo/Oxy <i>Presbyopia</i>		✓ Ph. IIb completed	Ph. III initiation	
GI	CVC <i>NASH</i>	Ph. III initiated	Ph. II combination CVC/Tropifexor		
	Relamorelin <i>Gastroparesis</i>	Ph. III initiated			Ph. III topline results
	Brazikumab <i>Crohn's</i>	Ongoing Ph. II	Ph. III initiation		1 st Ph. III topline results
	Brazikumab <i>UC</i>		✓ Ph. II initiation		
MA	Botox <i>Platysma/Masseter</i>	Ongoing Ph. IIb/III		Ph. IIb US initiation (Masseter and Platysma)	
	Fillers <i>Voluma, Volite, Elastagen</i>			Launch Volux (ex-US)	Launch Voluma Chin (US)